SecBot SecBot
SECBOTREPLAY Home › Report › SLN

SLN · Silence Therapeutics filed an updated corporate presentation on June…

Silence Therapeutics plc · 8-K filed Jun 23, 2026 at 16:35 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 23, 2026 at 16:35 ET

Silence Therapeutics filed an updated corporate presentation on June 23, 2026, highlighting pipeline progress across its siRNA programs. Key milestones include expected topline Phase 2 results for divesiran in polycythemia vera in 3Q 2026, Phase 1 data for SLN312 in dyslipidemia, and preclinical updates for SLN365 (GPR146) and SLN098 (INHBE). No financial data or guidance was provided.

  • Filed updated corporate presentation under Item 7.01 Regulation FD Disclosure
  • SANRECO Phase 2 study for divesiran (TMPRSS6) in polycythemia vera fully enrolled; topline results expected in 3Q 2026
  • SLN312 (ANGPTL3) Phase 1 data presented at 2026 EAS Congress showing robust ANGPTL3 reductions; Silence to re-gain exclusive rights post-Phase 1
  • SLN365 (GPR146) demonstrated >80% mRNA knockdown in NHP; potential IND filing in 2H 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access